Head to Head Contrast: Bonk (BNKK) versus Its Peers

Bonk (NASDAQ:BNKK – Get Free Report) is one of 345 publicly-traded companies in the “Financial Services” industry, but how does it contrast to its rivals? We will compare Bonk to similar companies based on the strength of its analyst recommendations, valuation, institutional ownership, profitability, earnings, dividends and risk.

Analyst Recommendations

This is a summary of current recommendations and price targets for Bonk and its rivals, as reported by MarketBeat.

As a group, “Financial Services” companies have a potential upside of 4.15%. Given Bonk’s rivals stronger consensus rating and higher probable upside, analysts plainly believe Bonk has less favorable growth aspects than its rivals.

Valuation & Earnings

This table compares Bonk and its rivals top-line revenue, earnings per share (EPS) and valuation.

Bonk’s rivals have higher revenue and earnings than Bonk. Bonk is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Risk & Volatility

Bonk has a beta of 2.04, suggesting that its share price is 104% more volatile than the S&P 500. Comparatively, Bonk’s rivals have a beta of 2.26, suggesting that their average share price is 126% more volatile than the S&P 500.

Institutional and Insider Ownership

12.6% of Bonk shares are held by institutional investors. Comparatively, 43.0% of shares of all “Financial Services” companies are held by institutional investors. 51.6% of Bonk shares are held by company insiders. Comparatively, 21.9% of shares of all “Financial Services” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Bonk and its rivals’ net margins, return on equity and return on assets.

Summary

Bonk rivals beat Bonk on 12 of the 13 factors compared.

Bonk Company Profile

(Get Free Report)

Safety Shot, Inc., a wellness and functional beverage company, engages in the research and development of over-the-counter products and intellectual property. Its products pipeline includes Photocil to address psoriasis and vitiligo; JW-700 to treat hair loss; JW-500 for women’s sexual wellness; NoStingz, a jellyfish sting prevention sunscreen; and JW-110 for the treatment of atopic dermatitis/eczema. The company primarily sell its products through third-party physical retail stores and partners. The company was formerly known as Jupiter Wellness, Inc. and changed its name to Safety Shot, Inc. in September 2023. The company was incorporated in 2018 and is headquartered in Jupiter, Florida.